Adam Goulburn is a senior associate with Lux Capital, based in the firm's New York headquarters. Adam concentrates on investments within the healthcare and life science sectors, including healthcare IT, services, mobile health and therapeutics. Adam has worked extensively with a number of Lux portfolio companies including Kyruus, Tech Care, Kala Pharmaceuticals and Genocea Biosciences. He is also a mentor for healthcare incubators Blueprint Health, Healthbox, TigerLabs and Aging2.0.
Everyone knows that Obamacare’s intention is to change the care delivery model from fee-for-service to fee-for-quality. The biggest question for me is how long it takes for this transition to take place. Hospitals are at the epicenter for care delivery in this country (whether they should or shouldn’t be is a debate for another time). […]
I read an interesting Wall Street Journal article recently that discussed the war between tech companies to control future consumer distribution platforms. The article explains that the cash-flush giants “…each want to own the digital platform where people communicate, shop and seek entertainment.” This got me thinking about platforms in healthcare. Right now, it’s fair […]
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.